Toggle Health Problems and D

Vitamin D levels in 56 countries (many have less than 20 ng) – 2021

Vitamin D in the time of the coronavirus (COVID-19) pandemic – a clinical review from a public health and public mental health perspective

Therapeutic Advances in Psychopharmacology, https://doi.org/10.1177/20451253211027699
Ursula Werneke, Fiona Gaughran, David M. Taylor

% of population <10ng or < 20ng from three studies

Females are highlighted in yellow
References (2014, 2017, 2019)

  • 37. Palacios C and Gonzalez L. Is vitamin D deficiency a major global public health problem? J Steroid Biochem Mol Biol 2014; 144 Pt A: 138–145. See VitaminDWiki Vitamin D deficiency is a major global public health problem – Maps Nov 2013
  • 38. Lips P, Cashman KD, Lamberg-Allardt C, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. Eur J Endocrinol 2019; 180: 23–54.
  • 39. van Schoor N and Lips P. Global overview of vitamin D status. Endocrinol Metab Clin North Am 2017; 46: 845–870

Note: Many Vitamin D studies are made in the cities (higher air pollution & less noon-time sun),
both of which result in lower levels of vitamin D than in rural areas
But, hospitals tend to have fewer % of low-income patients - who often have dark skins

Deficiency of Vitamin D category starts with the following

434 items   Some Highlights:

 Download the PDF from VitaminDWiki

Individuals with serious mental disorders (SMD) may have a higher risk of vitamin D (VIT-D) deficiency. They also experience higher mortality because of coronavirus disease 2019 (COVID-19) infection. Therefore, we have conducted a comprehensive review to examine the significance of VIT-D for public health and public mental health during the ongoing COVID-19 pandemic.

This review had three specific aims, from a global perspective to

  • (a) create a profile of VIT-D and review the epidemiology of VIT-D deficiency,
  • (b) explore VIT-D deficiency as risk factor for SMD and COVID-19 infections and
  • (c) examine the effectiveness of VIT-D supplementation for both conditions.

We found that, in terms of SMD, the evidence from laboratory and observational studies points towards some association between VIT-D deficiency and depression or schizophrenia. Mendelian randomisation studies, however, suggest no, or reverse, causality. The evidence from intervention studies is conflicting.

Concerning COVID-19 infection, on proof of principle, VIT-D could provide a plausible defence against the infection itself and against an adverse clinical course. But data from observational studies and the first preliminary intervention studies remain conflicting, with stronger evidence that VIT-D may mitigate the clinical course of COVID-19 infection rather than the risk of infection in the first place. From a public health and public mental health point of view, based on the currently limited knowledge, for individuals with SMD, the benefits of VIT-D optimisation through supplementation seem to outweigh the risks. VIT-D supplementation, however, should not substitute for vaccination or medical care for COVID-19 infection.

Created by admin. Last Modification: Monday July 12, 2021 17:35:32 GMT-0000 by admin. (Version 8)

Attached files

ID Name Comment Uploaded Size Downloads
15902 Percent C.jpg admin 12 Jul, 2021 16:38 66.94 Kb 231
15901 Percent B.jpg admin 12 Jul, 2021 16:38 94.23 Kb 231
15900 Percent A.jpg admin 12 Jul, 2021 16:37 85.83 Kb 239
15899 Vitamin D in the time of the coronavirus (COVID-19) July 2021 RG.pdf PDF 2021 admin 12 Jul, 2021 16:37 790.32 Kb 254